Randomized trial demonstrates targeted therapy efficacy in lung cancer, suggesting a novel approach for treatment.
Key Points
This work aims to develop a targeted therapy for non-small cell lung cancer (NSCLC) by using active ingredients from Tetrastigma hemsleyanum.
Developed a pH/photothermal dual-responsive nanocarrier (KMPB@PL-HA) loading kaempferol (KAE).
Utilized mesoporous Prussian blue (MPB) for photothermal core, with polylysine (PLL) and ultra-active hyaluronic acid (UL-HA) as responsive components.
Examined interactions of UL-HA with CD44 receptors in the tumor microenvironment to enhance drug uptake.
KAE induced mitochondrial apoptosis by inhibiting p-Akt and regulating Bax/Bcl-2 ratios.
Downregulation of VEGF and modulation of tumor microenvironment's redox homeostasis were observed.
Chemo-photothermal synergistic strategy showed enhanced antitumor effects in NSCLC treatment.